• The main reason why we employ the Beacon® system here at Abveris is to enable deep characterization of single B cells in multiple sequential assays. Its design allows for precise control over the movement of cells, leaving you with the ultimate flexibility in assay design and, as a result, higher screening resolution.
    Colby A. Souders, PhD, Chief Scientific Officer, Abveris.
  • We are getting clones at about 50-100% higher productivity than we were with our traditional system.
    Greg Bleck, PhD, Global Head of R&D, Catalent Biologics.
  • In the long run, this technology will help us to solve complex problems that are too hard or expensive to solve with our current tools.
    Philip Tagari, Vice President of Therapeutic Discovery, Amgen.